ahlam1399
09-03-2015, 12:01 PM
**vartis launches Neupogen copycat Zarxio in U.S. market
ZURICH, Sept 3 (Reuters) - **vartis AG has launched the first biosimilar drug in the United States after a U.S. appeals court declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/49871ab9/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=45anKDcGFqM:zqsmOvA5XnQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=45anKDcGFqM:zqsmOvA5XnQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=45anKDcGFqM:zqsmOvA5XnQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=45anKDcGFqM:zqsmOvA5XnQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=45anKDcGFqM:zqsmOvA5XnQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/45anKDcGFqM
ZURICH, Sept 3 (Reuters) - **vartis AG has launched the first biosimilar drug in the United States after a U.S. appeals court declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/49871ab9/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=45anKDcGFqM:zqsmOvA5XnQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=45anKDcGFqM:zqsmOvA5XnQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=45anKDcGFqM:zqsmOvA5XnQ:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=45anKDcGFqM:zqsmOvA5XnQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=45anKDcGFqM:zqsmOvA5XnQ:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/45anKDcGFqM